Dow Up0.07% Nasdaq Up0.61%

Inovio Pharmaceuticals, Inc. (INO)

9.89 Down 0.15(1.49%) 4:00PM EST
|After Hours : 9.89 0.00 (0.00%) 5:58PM EST - Nasdaq Real Time Price
ProfileGet Profile for:
Inovio Pharmaceuticals, Inc.
Building 18
Suite 400
Blue Bell, PA 19422
United States - Map
Phone: 267-440-4200
Fax: 267-440-4242

Index Membership:N/A
Full Time Employees:71

Business Summary 

Inovio Pharmaceuticals, Inc., together with its subsidiaries, discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company’s DNA-based SynCon technology designed to provide protection against known and new unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company’s clinical programs include HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Blue Bell, Pennsylvania.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Inovio Pharmaceuticals, Inc.

Corporate Governance 
Inovio Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 6; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. J. Joseph Kim Ph.D., 45
Chief Exec. Officer, Pres, Director and Member of Fin. Committee
Mr. Peter D. Kies , 51
Chief Financial Officer and Principal Accounting Officer
Dr. Niranjan Y. Sardesai Ph.D., 46
Chief Operating Officer
Dr. Mark L. Bagarazzi M.D., 53
Chief Medical Officer
Mr. Bernie Hertel ,
VP of Investor Relations and Communications
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders